Fable Therapeutics Appoints David J. Baker, PhD, as Chief Scientific Officer
Article content
CAMBRIDGE, Mass. — Fable Therapeutics, a discovery-stage biotechnology company developing purpose-built biologics powered by state-of-the-art structure and sequence-based protein language models, today announced the appointment of David J. Baker, PhD, as Chief Scientific Officer (CSO).
Article content
'David's extensive experience in drug discovery, with a strong track record of high performance and scientific leadership across the cardio-metabolic therapeutic area, makes him an ideal leader to advance our portfolio,' said Geoff MacKay, President & CEO of Fable. 'We are excited to welcome David to our leadership team and for him to guide Fable's scientific strategy and innovative platform.'
Article content
Dr. Baker contributes deep expertise leading highly successful teams from across industry and academia. Prior to joining Fable, Dr. Baker was Head of Metabolism Bioscience for Cardiovascular, Renal and Metabolism (CVRM) at AstraZeneca plc. He was responsible for guiding the metabolism portfolio from target selection to Ph2b in diabetes, obesity, MASH and dyslipidemia.
Article content
Dr. Baker joins Fable at a pivotal time to oversee the company's scientific strategy from discovery through to IND and first-in-human studies. 'I'm thrilled to be joining such a groundbreaking company with extremely talented individuals and looking forward to bringing new therapies to patients,' said Dr. Baker.
Article content
About Fable Therapeutics, Inc.
Article content
Fable Therapeutics, Inc. (Fable) is a discovery-stage biotechnology company that aims to improve the lives of the millions of people living with metabolic diseases including obesity and related comorbidities. Founded by veteran biotech entrepreneurs and leading computational scientists and backed by top-tier venture capital firms, Fable is applying an industry-leading sequence- and structure-based machine learning platform to design and optimize next-generation protein-based therapeutics. Fable's pipeline of therapeutics addresses validated target biology that has not yet been fully exploited owing to technical and development hurdles that are addressed by Fable's ML-enabled protein design engine.
Article content
Backed by a 2024 $43.5M Series A investment co-led by Versant Ventures and DCVC, Fable is leading in the purposeful integration of biology and computation to solve complex medical challenges. Fable's aspiration is to write the next chapter of what protein-based therapeutics can do, both through its internal pipeline and research and development partnerships with pharmaceutical companies. Fable has locations in Cambridge, MA and Toronto, Canada.
Article content
Article content
Article content
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
38 minutes ago
- Globe and Mail
From Craft to Commerce: Creative Rubber Stamps Says Businesses Are Now Driving Spike in Custom Signature Stamp Sales
Creative Rubber Stamps' founder, Gary Lay, highlights remote work, personalization, and legal compliances as key drivers. As small businesses and professionals look for smarter, more efficient ways to handle repetitive paperwork, Creative Rubber Stamps is seeing a significant surge in demand for its self-inking signature stamps. Recent industry research reported that the global rubber stamp market is on track to grow at a CAGR of 4.05% from 2025 to 2033. This growth is projected to be driven by increased documentation requirements, brand personalization, and the growing need for time-saving innovations. Once considered a niche craft tool, rubber stamps have not only entered the mainstream business world but have become essential business accessories. According to the founder of Creative Rubber Stamps, Gary Lay, the rise in custom stamp usage among small businesses represents a significant shift in the industry. He explained that custom self-inking signature stamps are quickly replacing the outdated print-sign-scan routine for businesses. Due to their affordability, branding potential, efficiency, and record-keeping benefits, custom signature stamps have become a way for businesses to leave a recognizable, professional mark on every transaction. Many small businesses are now using custom self-inking stamps to sign documents, maintain signature consistency, and speed up their internal operations – all while adding a professional touch. 'We have watched the rubber stamp market evolve over the years, but this shift has been momentous,' said Gary. 'More professionals are realizing that they don't need to go through the tedious printing, signing, and scanning process when they can opt for custom signature stamps that save time, improve accuracy, and add a layer of professionalism.' Creative Rubber Stamps embraces this growth by sharpening its focus on innovation and customer experience. One of Creative Rubber Stamps' competitive advantages is its signature self-inking stamps, which offer clean signatures in ink with a single press. Unlike traditional stamps that require a separate ink pad, the self-inking models automatically re-ink, allowing for hundreds of crisp, clean impressions before needing a refill. Beyond the speed and convenience, these signature stamps also help people maintain consistency across documents and reduce the chances of signature errors, smudges, and forgery. To ensure quality, Creative Rubber Stamps carries the best customizable stamp brands in the market, Trodat, a brand that is recognized as the world's top manufacturer of self-inking stamp cases. All customers have to do on Creative Rubber Stamps' site is select the Trodat brand stamp they want for their custom signature. Creative Rubber Stamps also ensures that each signature stamp is laser engraved in rubber for a crisp, cleaner image. Moreover, the company offers a preview function for clients after uploading their artwork, which allows them to visualize how it will look on the finished stamp. This also gives them an opportunity to make design and size adjustments before placing their order. With custom stamps starting at $20, Creative Rubber Stamps has established itself as the go-to custom stamps. Creative Rubber Stamps has seen the spike in custom signature sales come from the legal, healthcare, and financial sectors, where document approval is a constant task. With thousands of satisfied customers, infinite customization options, and a vast product catalog that includes address stamps, notary stamps, logo stamps, monogram stamps, and date stamps, Creative Rubber Stamps has established itself as a staple vendor for small businesses seeking speed, efficiency, and polish. The company, which boasts over 30 years of design and stamp experience, continues to carve out its space in the growing market by offering professionals and small businesses access to customizable signature stamps that they can instantly preview. Gary reaffirmed that he and his team are excited to continue helping time-starved professionals secure self-inking signature stamps. 'We love how versatile stamps are. I believe that is why they are catching on so quickly, especially for small businesses,' he said. 'My team and I are excited to see something we are so passionate about become widely adopted by professionals and businesses and commit to continuing to help our customers create custom stamps that are uniquely theirs.' He concluded by saying that the company's growth has been driven by its dedication to serving clients and keeping pace with market trends. 'Our growth has come from listening to customers and staying up to date on market trends. We are not just selling stamps; we are giving people tools that make workdays easier.' Visit Creative Rubber Stamps to explore its full collection of custom rubber stamps. Media Contact Company Name: Creative Rubber Stamps Contact Person: Gary Lay Email: Send Email Country: United States Website:
Globe and Mail
an hour ago
- Globe and Mail
Why AppFolio Stock Rocked the Market on Tuesday
One quite active stock mover on a forgettable Tuesday for the market was specialized business software developer AppFolio (NASDAQ: APPF). The company's shares saw a robust rise of almost 5% across the trading day, thanks to a pair of insider stock buys disclosed in regulatory filings. On that day, the S&P 500 (SNPINDEX: ^GSPC) also rose but by nowhere near as much, inching up to close the day 0.6% higher. A pair of very familiar stock buyers The two AppFolio folks snapping up shares of the company were members of its board of directors, Timothy Bliss and Casey Donald. Of the pair, Bliss was the more assertive, as he amassed 22,000 shares in a series of buys between last Thursday and the following Monday. The per-share price he paid for each of these blocks ranged from $215.28 to $218.73. Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue » As for Donald, his buying activity was more muted and concentrated. In a single purchase made last Friday, he snapped up 4,000 shares, paying an average of $217.73 apiece for the privilege. Shares of AppFolio, a software-as-a-service (SaaS) company that focuses on the real estate market, have seen something of an upswing lately. In no small part, this is a recovery from a sell-off following the company's first-quarter earnings release, published in late April. Although it posted solid growth on the top line, its net income fell, and it missed analyst estimates for both metrics. Lofty expectations We should bear in mind that investor expectations for the often-prosperous SaaS segment can be awfully high. Often, folks invested in industry titles demand not only strong, across-the-board growth; they insist on crushing beats too. To me, AppFolio is still doing very well in its niche, and remains robustly profitable despite that recent bottom-line dip. I think those insider buys were smart. Should you invest $1,000 in AppFolio right now? Before you buy stock in AppFolio, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and AppFolio wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $660,341!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $874,192!* Now, it's worth noting Stock Advisor 's total average return is999% — a market-crushing outperformance compared to173%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of June 9, 2025
Globe and Mail
an hour ago
- Globe and Mail
Why Nvidia-Backed Navitas Semiconductor Soared Today
Shares of Navitas Semiconductor (NASDAQ: NVTS) surged higher on Tuesday, finishing the day up 11%. The gain came as the S&P 500 (SNPINDEX: ^GSPC) and the Nasdaq Composite (NASDAQINDEX: ^IXIC) were both up 0.6%. Positive news from ongoing trade talks between the U.S. and China is helping boost the company's stock as it continues its massive run-up following the revelation of its partnership with Nvidia. U.S. and China trade talks continue U.S. and Chinese officials are in London attempting to reach a more permanent resolution to the trade war that was put on pause last month. Commerce Secretary Howard Lutnick said on Tuesday that the discussions were "going well" and that the representatives were "spending lots of time together" attempting to reach a deal. A permanent reduction of the massive tariffs both countries imposed on each other in recent months would be great news for the entire economy, but semiconductor companies could benefit specifically, depending on the details. A critical partner Navitas announced last month that Nvidia had selected the company to help power its next-generation artificial intelligence (AI) data center systems, including the much-anticipated Rubin chips that will eventually succeed the current industry-leading Blackwell chips. Navitas, which specializes in gallium nitride (GaN) and silicon carbide (SiC) technologies, will help Nvidia solve key scaling issues with its power supply for the incredibly powerful AI-fueled chips. I think Navitas stock is worth owning; the seal of approval from Nvidia is huge. The company's balance sheet is solid, with minimal debt. Should you invest $1,000 in Navitas Semiconductor right now? Before you buy stock in Navitas Semiconductor, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Navitas Semiconductor wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $660,341!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $874,192!* Now, it's worth noting Stock Advisor 's total average return is999% — a market-crushing outperformance compared to173%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of June 9, 2025
